The path forward for anti-programmed cell death-1 therapy in gliomas

Area of Science:

• Oncology
• Immunotherapy
• Cancer Research

Background:

• Checkpoint inhibitors (CPIs) are leading immunotherapies for solid tumors.
• Glioblastoma (GBM) presents challenges for CPIs due to its immunosuppressive microenvironment and low tumor mutation burden.

Purpose of the Study:

• Review mechanisms of PD-1 blockade success in hypermutated GBM.
• Analyze clinical trials of anti-PD-1 monotherapy and combination approaches in GBM.
• Discuss immunotherapy resistance and strategies to overcome challenges in GBM.

Main Methods:

• Literature review of clinical trials and studies on CPIs in GBM.
• Analysis of patient subsets responding to PD-1 blockade.
• Exploration of neoadjuvant and combination immunotherapy strategies.

Main Results:

• Phase III trials showed CPIs were not superior to standard care in GBM.
• A Phase II study indicated improved survival with neoadjuvant anti-PD-1 therapy in recurrent GBM.
• Responses to anti-PD-1 therapy observed in GBM patients with hypermutator tumors.

Conclusions:

• Anti-PD-1 therapy may not benefit unselected GBM patients.
• PD-1 blockade success in specific GBM subsets (e.g., hypermutated tumors) is encouraging.
• Further investigation into tailored immunotherapy approaches for GBM is warranted.